ReviewThe European respiratory journal2020
Host-microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease.
Review in The European respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research status and development trends of chronic obstructive pulmonary disease and gut microbiota: a comprehensive analysis based on bibliometrics and knowledge visualization.Frontiers in microbiology · 2026Pooled it
- Trial
- Short-term stability of the sputum microbiota in bronchiectasis and cystic fibrosis.ERJ open research · 2025Article
- The Respiratory Tract Microbiome and Human Health.Microbial biotechnology · 2025Review
- Affinity of Malassezia and Other Yeasts for Pulmonary Lipids.Mycopathologia · 2024Article
- Lung Microbiota in Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, and Unclassified Interstitial Lung Diseases: A Preliminary Pilot Study.Diagnostics (Basel, Switzerland) · 2023Article
- Cytokine-targeted therapies for asthma and COPD.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Exploration of lung mycobiome in the patients with non-small-cell lung cancer.BMC microbiology · 2023Article
- Article
- The impact of bacterial exposure in early life on lung surfactant gene expression, function and respiratory rate in germ-free mice.Frontiers in microbiomes · 2023Article
- Therapeutic Targeting of the Respiratory Microbiome.American journal of respiratory and critical care medicine · 2022Article
- The effect of organ-specific tumor microenvironments on response patterns to immunotherapy.Frontiers in immunology · 2022Review
- Single Nucleotide Polymorphisms (SNP) and SNP-SNP Interactions of the Surfactant Protein Genes Are Associated With Idiopathic Pulmonary Fibrosis in a Mexican Study Group; Comparison With Hypersensitivity Pneumonitis.Frontiers in immunology · 2022Article
- Dysbiosis in Pediatrics Is Associated with Respiratory Infections: Is There a Place for Bacterial-Derived Products?Microorganisms · 2021Review
- Exposure to the gut microbiota from cigarette smoke-exposed mice exacerbates cigarette smoke extract-induced inflammation in zebrafish larvae.Current research in immunology · 2021Article
- A sneak peek into the Early Career Members' session at the ERS International Congress and the experience of organising an ERS Research Seminar.Breathe (Sheffield, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic respiratory diseases are highly prevalent worldwide and will continue to rise in the foreseeable future. Despite intensive efforts over recent decades, the development of novel and effective therapeutic approaches has been slow. However, there is new and increasing evidence that communities of micro-organisms in our body, the human microbiome, are crucially involved in the development and progression of chronic respiratory diseases. Understanding the detailed mechanisms underlying this cross-talk between host and microbiota is critical for development of microbiome- or host-targeted therapeutics and prevention strategies. Here we review and discuss the most recent knowledge on the continuous reciprocal interaction between the host and microbes in health and respiratory disease. Furthermore, we highlight promising developments in microbiome-based therapies and discuss the need to employ more holistic approaches of restoring both the pulmonary niche and the microbial community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.